Insider Selling: Collegium Pharmaceutical, Inc. (NASDAQ:COLL) CFO Sells 977 Shares of Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) CFO Colleen Tupper sold 977 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $30.00, for a total transaction of $29,310.00. Following the sale, the chief financial officer now directly owns 164,269 shares of the company's stock, valued at $4,928,070. This represents a 0.59 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Colleen Tupper also recently made the following trade(s):

• On Tuesday, March 11th, Colleen Tupper sold 10,445 shares of Collegium Pharmaceutical stock. The shares were sold at an average price of $30.01, for a total transaction of $313,454.45.
• On Thursday, March 6th, Colleen Tupper sold 1,949 shares of Collegium Pharmaceutical stock. The stock was sold at an average price of $30.00, for a total transaction of $58,470.00.

Collegium Pharmaceutical Price Performance

Shares of Collegium Pharmaceutical stock traded up $0.12 during trading hours on Friday, reaching $30.05. The stock had a trading volume of 2,287,750 shares, compared to its average volume of 417,801. The stock's 50 day moving average is $30.69 and its 200 day moving average is $32.71. The firm has a market capitalization of $946.15 million, a PE ratio of 12.95 and a beta of 0.99. Collegium Pharmaceutical, Inc. has a twelve month low of $27.28 and a twelve month high of $42.29. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43.

Remove Ads

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, topping analysts' consensus estimates of $1.54 by $0.09. The business had revenue of $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. Equities analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of COLL. Invesco Ltd. increased its stake in shares of Collegium Pharmaceutical by 19.5% during the fourth quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company's stock worth $50,876,000 after purchasing an additional 289,335 shares in the last quarter. Principal Financial Group Inc. increased its stake in shares of Collegium Pharmaceutical by 3.9% during the third quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company's stock worth $67,459,000 after purchasing an additional 64,958 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Collegium Pharmaceutical by 0.3% during the fourth quarter. Renaissance Technologies LLC now owns 1,661,549 shares of the specialty pharmaceutical company's stock worth $47,603,000 after purchasing an additional 5,480 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Collegium Pharmaceutical by 0.7% during the third quarter. Geode Capital Management LLC now owns 775,579 shares of the specialty pharmaceutical company's stock worth $29,974,000 after purchasing an additional 5,464 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA grew its stake in Collegium Pharmaceutical by 17.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 765,692 shares of the specialty pharmaceutical company's stock valued at $29,586,000 after acquiring an additional 116,327 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on COLL shares. Needham & Company LLC raised shares of Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price target on the stock in a report on Friday, January 10th. HC Wainwright reiterated a "buy" rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. Finally, Piper Sandler lowered their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a research note on Tuesday, February 4th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $43.60.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.